Q3 EPS Forecast for Elicio Therapeutics Decreased by Analyst

Elicio Therapeutics, Inc. (NASDAQ:ELTX) – HC Wainwright reduced their Q3 2026 EPS estimates for shares of Elicio Therapeutics in a note issued to investors on Tuesday, August 18th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.44) per share for the quarter, down from their prior estimate of ($0.39). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Elicio Therapeutics’ current full-year earnings is ($2.10) per share. HC Wainwright also issued estimates for Elicio Therapeutics’ Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.83) EPS, Q1 2027 earnings at ($0.35) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.38) EPS.

Several other equities research analysts also recently issued reports on ELTX. JonesTrading downgraded shares of Elicio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Rodman & Renshaw reaffirmed a “buy” rating on shares of Elicio Therapeutics in a research report on Monday, June 15th. Wall Street Zen raised Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. B. Riley Financial assumed coverage on shares of Elicio Therapeutics in a research note on Wednesday, June 10th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, LADENBURG THALM/SH SH started coverage on Elicio Therapeutics in a report on Thursday, June 18th. They set a “buy” rating and a $12.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.75.

Elicio Therapeutics Trading Up 0.6%

Shares of Elicio Therapeutics stock opened at $3.13 on Thursday. The business has a fifty day simple moving average of $3.80 and a two-hundred day simple moving average of $8.32. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.77 and a quick ratio of 2.77. The company has a market capitalization of $59.75 million, a price-to-earnings ratio of -1.44 and a beta of 1.30. Elicio Therapeutics has a 1 year low of $2.66 and a 1 year high of $16.00.

Elicio Therapeutics (NASDAQ:ELTX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.11.

Institutional Investors Weigh In On Elicio Therapeutics

Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its stake in Elicio Therapeutics by 186.8% in the third quarter. Bank of America Corp DE now owns 3,585 shares of the company’s stock valued at $39,000 after purchasing an additional 2,335 shares in the last quarter. Geode Capital Management LLC increased its holdings in Elicio Therapeutics by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 132,518 shares of the company’s stock worth $1,055,000 after purchasing an additional 2,832 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Elicio Therapeutics in the 2nd quarter valued at $46,000. State Street Corp raised its holdings in shares of Elicio Therapeutics by 20.9% in the fourth quarter. State Street Corp now owns 46,300 shares of the company’s stock valued at $369,000 after purchasing an additional 8,000 shares during the last quarter. Finally, Summit Financial LLC purchased a new stake in Elicio Therapeutics in the 4th quarter valued at about $80,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.